Dr Yada Kanjanapan is a Medical Oncologist at The Canberra Hospital, and Clinical Senior Lecturer at the Australian National University. Her clinical sub-specialties are in breast and gynaecological cancers, melanoma and developmental therapeutics.

Dr Kanjanapan has expertise in cancer immunotherapy and early-phase clinical trials through a two-year fellowship at the Princess Margaret Cancer Centre, Toronto, Canada. Her research track record includes leading a number of completed projects, in areas such as hypergrogressive disease in immunotherapy, and kinetics of immune-related adverse events in relation to dose-limiting toxicity determination. She has also been a clinical investigator in multiple early-phase trials.

Dr Kanjanapan also has an interest in the COVID-19 pandemic with regards to impact on oncological care and outcome in cancer patients. She has written a perspective piece on "Considerations for cancer immunotherapy during the COVID-19 pandemic", published in the Medical Journal of Australia. She is the lead author in the Medical Oncology Group of Australia Position Statement on COVID-19 vaccination in patients with solid tumours. Dr Kanjanapan is currently leading the EVEREST (Evaluation of COVID-19 Vaccination Efficacy and Rare Events in Solid Tumours) study at The Canberra Hospital, in collaboration with the Australian National University.

Publications list:

https://scholar.google.com.au/citations?user=htt7hwwAAAAJ&hl=en